News

Alfa Wassermann buys licence
Enlarge image

BusinessItaly

Alfa Wassermann buys licence

05.10.2012 - Italian Alfa Wassermann has acquired an exclusive licence for Theravance’s serotonin 5-HT4 agonist velusetrag.

The US biotech partner can bag up to US$63.5 plus royalties for the exclusive development and commercialisation rights of the treatment for gastrointestinal motility disorders such as constipation, irritable bowel syndrome, functional dyspepsia, and gastroparesis. The Bologna-headquartered pharma firm Alfa Wassermann, will fund Phase II clinical trials and grant Theravance a US$10m option fee payable if Alfa Wassermann exercises its option for Europe, Russia, China,  and other key markets after clinical proof-of-concept. The San Francisco-based biotech firm also is set to receive development, regulatory and sales milestone payments of up to US$53.5m. Additionally it may earn royalties on net sales of velusetrag (TD-5108) up to 20%.

What makes velusetrag so attractive to the Italians is its, up-to-now, beneficial safety profile. Previous treatments for gastrointestinal (GI) dysmotility targeting the 5-hydroxytryptamine(4) receptor, modified the function of the cardiac HERG potassium channel leading to severe adverse effects. Within the Phase II programme, the Italian firm will evaluate the efficacy, safety and tolerability of once-daily oral velusetrag in the treatment of patients with gastroparesis. The disorder has few therapeutic options and it is characterised by delayed gastric emptying in the absence of a mechanical obstruction with symptoms that include early satiety, nausea, vomiting and bloating. Velusetrag has been shown to accelerate gastric emptying in healthy volunteers.

Theravance will retain the full rights to the drug in the US, Canada, Japan and certain other countries. The US firm has completed a 400-patient Phase II proof-of-concept study in chronic idiopathic constipation for the drug. In the trial the compound demonstrated statistically significant prokinetic activity at all three doses (15 mg, 30 mg, and 50 mg) tested.

It was generally well tolerated and showed a low incidence of adverse events at the two lowest doses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/alfa-wasserman-buys-theravance-licence.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • TIGENIX (B)1.28 EUR25.49%
  • BIOTECH PHARMACON (N)14.35 NOK13.89%
  • BIOFRONTERA (D)2.25 EUR10.29%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-39.13%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • MEDIGENE (D)7.58 EUR-5.60%

TOP

  • KARO BIO (S)39.40 SEK2378.0%
  • TRANSGENE (F)5.02 EUR74.9%
  • TIGENIX (B)1.28 EUR62.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.99 EUR-40.7%
  • BIONOR PHARMA (N)1.25 NOK-39.0%

TOP

  • KARO BIO (S)39.40 SEK4704.9%
  • ADOCIA (F)86.21 EUR408.0%
  • GALAPAGOS (B)53.99 EUR328.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • EVOCUTIS (UK)0.19 GBP-80.2%
  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-78.5%

No liability assumed, Date: 01.09.2015